Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TENDOSHOCK: Combined Therapy for Athletic Tendinopathies
NCT01185951Phase 2Unknown
- Sponsor
- Hannover Medical School
- Start
- Jan 2007
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 10XB101 and nitroglycerin in Achilles tendinopathy, patellar tendinopathy and epicondylitis, sponsored by Hannover Medical School. Primary endpoints: Victorian Institute of Sport Assessment-Achilles up to 4 years, Victorian Institute of Sport Assessment-Patella up to 4 years and 1 more. Status: unknown.
02
Drugs
10XB101nitroglycerin
03
Conditions
Achilles tendinopathypatellar tendinopathyepicondylitis
Beyond the preview
Go deeper on NCT01185951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01185951.